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Background: Screening programmes for type 2 diabetes inevitably find more individuals at high risk for diabetes
than people with undiagnosed prevalent disease. While well established guidelines for the treatment of diabetes
exist, less is known about treatment or prevention strategies for individuals found at high risk following screening.
In order to make better use of the opportunities for primary prevention of diabetes and its complications among
this high risk group, it is important to quantify diabetes progression rates and to examine the development of early
markers of cardiovascular disease and microvascular diabetic complications. We also require a better understanding
of the mechanisms that underlie and drive early changes in cardiometabolic physiology. The ADDITION-PRO study
was designed to address these issues among individuals at different levels of diabetes risk recruited from Danish
primary care.
Methods/Design: ADDITION-PRO is a population-based, longitudinal cohort study of individuals at high risk for
diabetes. 16,136 eligible individuals were identified at high risk following participation in a stepwise screening
programme in Danish general practice between 2001 and 2006. All individuals with impaired glucose regulation at
screening, those who developed diabetes following screening, and a random sub-sample of those at lower levels
of diabetes risk were invited to attend a follow-up health assessment in 2009–2011 (n = 4,188), of whom 2,082
(50%) attended. The health assessment included detailed measurement of anthropometry, body composition,
biochemistry, physical activity and cardiovascular risk factors including aortic stiffness and central blood pressure.
All ADDITION-PRO participants are being followed for incident cardiovascular disease and death.
Discussion: The ADDITION-PRO study is designed to increase understanding of cardiovascular risk and its
underlying mechanisms among individuals at high risk of diabetes. Key features of this study include (i) a carefully
characterised cohort at different levels of diabetes risk; (ii) detailed measurement of cardiovascular and metabolic
risk factors; (iii) objective measurement of physical activity behaviour; and (iv) long-term follow-up of hard clinical
outcomes including mortality and cardiovascular disease. Results will inform policy recommendations concerning
cardiovascular risk reduction and treatment among individuals at high risk for diabetes. The detailed phenotyping
of this cohort will also allow a number of research questions concerning early changes in cardiometabolic
physiology to be addressed.
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The increasing global prevalence of diabetes has led several
countries to propose or introduce screening programmes
for diabetes in the past decade [1,2]. These screening
programmes, which generally combine a structured assess-
ment of risk factors for diabetes with a measure of gly-
caemia, will inevitably find more individuals at high risk
for diabetes than those with undiagnosed prevalent disease.
The ADDITION-Europe study [3] included a stepwise
screening programme for diabetes in general practice in
Denmark, the UK and the Netherlands, and identified
more individuals with impaired fasting glycaemia (IFG) or
impaired glucose tolerance (IGT) than those with screen-
detected diabetes [4,5]. The screening programme also
identified large numbers with normal glucose levels des-
pite having one or more risk factors for diabetes or cardio-
vascular disease (CVD) [4]. While established guidelines
for treating individuals with diagnosed diabetes are avai-
lable [6], it remains unclear which treatment or prevention
strategies should be introduced among those found to be
at high risk of diabetes following screening. Development
of diabetes can be prevented by very intensive lifestyle
intervention among motivated individuals with IGT [7] but
no trials of diabetes prevention have been performed in
groups at lower absolute risk. Furthermore, there are no
large-scale studies of the association between diabetes risk,
dysglycaemia, and the development of the initial stages of
diabetic micro- and macrovascular complications.
In order to make better use of the opportunities for
primary prevention of diabetes and its complications
afforded by the identification of large groups of at-risk
individuals, there are a number of research questions
that require investigation. It is necessary to accurately
assess progression to diabetes in groups at different
levels of risk and to examine the development of early
markers of CVD and diabetic microvascular compli-
cations. A better understanding of the mechanisms that
underlie and drive early changes in cardiometabolic
physiology is also required.
To investigate these issues, we invited individuals at
different levels of diabetes risk identified from the step-
wise screening programme of the Danish arm of the
ADDITION-Europe study [3] to take part in a longitu-
dinal cohort study (ADDITION-PRO). The overall aim
of ADDITION-PRO is to increase understanding of CVD
risk and its underlying mechanisms among individuals at
different levels of diabetes risk. We will quantify the
incidence of diabetes and CVD in high risk individuals,
and examine diabetes and CVD progression using detailed
measures of anthropometry, body composition, bioche-
mistry, aortic stiffness and lifestyle behaviours. Results will
inform policy recommendations concerning CVD risk
reduction and treatment among individuals at high risk
for diabetes.Specific objectives of the ADDITION-PRO study
include:
■ To quantify progression rates from groups at
different levels of diabetes risk to IFG, IGT and
diabetes, and to examine the determinants of glycaemic
state transition
■ To establish whether initial levels of glycaemia and
subsequent transitions from one glycaemic state to
another affect the initial stages of micro- and
macrovascular complications, and the risk of incident
CVD and mortality
■ To examine the association between:
– objectively measured physical activity and markers
of glucose homeostasis
– anthropometric and body fat distribution measures,
markers of glucose homeostasis and the initial stages
of micro- and macrovascular complications
– deterioration in glucose metabolism, long-term
glycaemia and the development of initial stages of
micro- and macrovascular complications
Methods/Design
The ADDITION-PRO study is nested within the Danish
arm (ADDITION-DK) of the ADDITION-Europe study
[3,8]. ADDITION-DK consists of two phases: a population-
based stepwise screening programme for type 2 diabetes
and a randomised controlled trial of early intensive treat-
ment among those found to have diabetes. A subset of indi-
viduals identified at high risk for diabetes following the
screening phase of the study were invited to take part in
the longitudinal ADDITION-PRO cohort study. Ethical
approval was obtained from the scientific ethics committee
in the Central Denmark Region (no: 20000183). Partici-
pants gave written informed consent to take part in the
study and for linkage of their data with national registers
for the purposes of the ADDITION-PRO study.
ADDITION-DK stepwise screening programme
Full details of the screening programme are reported
elsewhere [9,10]. In brief, a population-based, stepwise
high-risk screening programme was performed in 190
general practices (GP) in five counties covering urban,
suburban and rural areas of Denmark (Copenhagen,
Aarhus, Ringkøbing, Ribe and South Jutland) from 2001
to 2006. Individuals eligible for invitation to screening
were people registered with one of the participating gen-
eral practices, aged 40 to 69 years, and not known to
have diabetes. Exclusion criteria were assessed by the
general practitioners and included pregnancy or lacta-
tion, being housebound, having a psychological or psy-
chiatric problem likely to invalidate informed consent,
or having an illness with a likely prognosis for life
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received a slightly modified version of the Danish dia-
betes risk questionnaire by post or were asked to
complete the questionnaire opportunistically while visit-
ing their GP [11,12]. Recipients were asked to indicate
known risk factors for diabetes including age, sex, BMI,
known hypertension, family history of type 2 diabetes,
gestational diabetes and leisure time physical activity.
Those with a risk score ≥ 5 points were invited to con-
tinue in the stepwise screening programme, which
included random blood glucose and HbA1c testing, a
fasting blood glucose test, and an oral glucose tolerance
test (OGTT). World Health Organisation criteria were
used to diagnose diabetes [13].
In ADDITION-DK, 163,189 individuals aged 40–69 years
were mailed the risk score questionnaire or filled it in
opportunistically at their GP. 26,491 had a diabetes risk
score ≥ 5 points and attended for a random blood glucose
and/or HbA1c measurement. Participants who completed
the screening programme and who were not found to
have diabetes (n = 22,200) were classified into groups of
increasing diabetes risk: (i) high diabetes risk (≥5 points
on diabetes risk score) with normoglycaemia (n = 19,968);Figure 1 ADDITION-DK screening programme.(ii) isolated IFG (n = 918); (iii) isolated IGT (n = 769); and
(iv) IFG and IGT (n = 545). In order to establish a group
at low risk of diabetes, between 2001 and 2002, a sub-
group of participants in Aarhus and Copenhagen county
from both the postal and opportunistic screening pro-
grammes (n = 32,894) were asked to return their risk
questionnaire regardless of their score. 13,288 individuals
with a low diabetes risk (<5 points on diabetes risk score)
were identified [12]. These stratified risk groups constitute
the sampling frame for the ADDITION-PRO study
(Figure 1).
ADDITION-PRO study
In 2009–2011, a follow-up health examination of a subset
of the stratified high risk population was performed at
four out of the five original ADDITION-DK study centres
to establish a longitudinal cohort. Individuals who were
eligible to be invited included those (i) who were still alive,
(ii) who lived in the regions of the four research centres
(Steno Diabetes Center, Aarhus University Hospital,
Holstebro Hospital, and Hospital of South West Jutland,
Esbjerg), and (iii) who had not withdrawn consent to study
participation. Of these 16,136 people, all individuals with
Johansen et al. BMC Public Health 2012, 12:1078 Page 4 of 10
http://www.biomedcentral.com/1471-2458/12/1078impaired glucose regulation at the time of screening and
those who were diagnosed with diabetes during the follow-
up period before the time of invitation were invited
(n = 1,483) as well as a 19% random sample of individuals
from the low and high risk groups (n = 2,705). In total,
2,082/4,188 (50%) people agreed to participate and attended
the ADDITION-PRO health assessment (Figure 2). Com-
pared to attenders, non-attenders were more likely to be
women and to have a normal weight, and were less likely to
have a family history of diabetes (Table 1). Participation did
not differ in terms of age, hypertension, history of gesta-
tional diabetes, or physical activity.
ADDITION-PRO health assessment
Health assessments were performed by trained staff follow-
ing standard operating procedures. See Table 2 for a full list
of measures taken during the screening programme and at
the ADDITION-PRO health assessment.
Clinical measures
A ten second 12-lead electrocardiogram (ECG) was
taken with the participant in a supine position. Brachial
blood pressure and heart rate was measured three times
after a 10 minute rest (Omron M6 comfort, Omron
Healthcare, Milton Keynes, UK) with the participant in a
sitting position. The average of the three measurements
for each parameter constitutes the values for brachial
systolic and diastolic blood pressure and heart rate.
Central haemodynamics (aortic pulse wave velocity
(aPWV) and central blood pressure) were assessed by
applanation tonometry using a SphygmoCor device (ver-
sion 8, Atcor Medical, West Ryde, NSW, Australia) and
a high fidelity tonometer. With the participant in supine
position after 10 minutes of rest, the velocity of theIFG+IGT
n=545
iIGT
n=769
iIFG
n=918
Individuals eligible for invitation to the ADDITION-PRO 
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Figure 2 Design and participant flow in the ADDITION-PRO study.pulse wave was assessed between the right carotid and
femoral artery. This is a validated method of assessing
aortic stiffness [15], an assessment of subclinical organ
damage. The tonometer was used to capture wave forms
at the carotid and subsequently at the femoral artery
simultaneously with an ECG recording using the intersec-
ting tangent [16]. The transit time was based on the mean
of ten pulse waves. The distance from the suprasternal
notch to the carotid artery was measured with a tape
measure and from the suprasternal notch to the femoral
artery with an anthropometer (Seca, Medical Scales and
Measuring Systems, Hamburg, Germany). The anthro-
pometer was used to avoid overestimation of the distance
and consequently the velocity in obese individuals. The
path length was determined by subtracting the carotid-
sternal notch distance from the femoral-sternal notch dis-
tance. In each participant, aPWV was measured twice. If
the difference in aPWV between the two measurements
was larger than 0.5 m/s, a third measurement was taken.
The average of the two closest measurements in each par-
ticipant constitutes the value of aPWV.
Central blood pressure, augmented pressure and aug-
mentation index were calculated from the peripheral pres-
sure waveforms recorded at the radial artery with the
participant in the supine position. The radial waveforms
were calibrated by the supine brachial systolic and dias-
tolic blood pressure based on a built-in generalised trans-
fer function. Supine brachial blood pressure was measured
after a 10-minutes rest with an automated oscillometric
blood pressure recorder (Omron M6 comfort). From the
central waveforms, central systolic and diastolic blood
pressure, pulse pressure, augmented pressure and aug-
mentation index were estimated. At least two measure-
ments were taken, and the average of each pressure indexHigh diabetes risk 
(score≥5) and 
normoglycaemia
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Low diabetes risk 
(score <5)
n=13,288
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Table 1 Difference in characteristics at screening between
attenders and non-attenders to the ADDITION-PRO study
Characteristics
at screening
Attenders
n = 2,082
Non-attenders
n = 2,106
p-value1
Men (%) 53.4 42.8 < 0.001
Median age
(years)
58.5 59.3 0.551
Gestational
diabetes
(% of women)
2.2 1.4 0.185
Family history
of diabetes (%)
No relatives 67.7 73.8 < 0.001
1 relative 24.3 19.6
2 relatives 6.1 5.0
Hypertension2
(%)
36.7 36.5 0.838
Weight (%) Normal
weight
36.0 40.2 0.006
Overweight 45.0 40.3
Obese 17.8 18.1
Physically
inactive3 (%)
78.1 78.1 0.856
1 p-value from t-tests or chi-squared test for the difference between attenders
and non-attenders.
2 Hypertension defined as “has a doctor ever told you that you have high
blood pressure” in the risk score questionnaire [12].
3 Classified as inactive from four questions pertaining to leisure time physical
activity in the risk score questionnaire [14].
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diastolic blood pressure, pulse pressure, augmentation
index and augmented pressure.
Advanced glycation end-products (AGE) were measured
by skin autofluorescence using an AGE-reader (Diagnoptics
Technologies B.V, Groningen, The Netherlands). The mea-
surement is based on illumination of a ~ 4 cm2 area of skin
on the volar side of the forearm with light (wavelength of
300–420 nm), which excites fluorescent moieties in the
skin. Autoflourescence, the fluorescent light subsequently
emitted from the skin (wavelengths of 420–600 nm), is
measured by an integrated spectrometer and expressed as
the ratio between the intensity of the emitted fluorescent
light and the excitation light [17]. AGE measurements were
taken on the right forearm preceded by the removal of dead
skin cells with alcohol preparation pads. One measurement
session consisted of three AGE measures, and in each par-
ticipant three sessions were completed. The average of the
three sessions is regarded as the AGE value.Anthropometric measures
Height was measured to the nearest millimetre using a
fixed rigid stadiometer (Seca, Medical Scales and Measur-
ing Systems, Hamburg, Germany). Weight was measured
in light indoor clothing without shoes to the nearest
0.1 kg with a Tanita Body Composition Analyser (Tokyo,Japan). Clothes were estimated to weigh 0.5 kg and this
weight was deducted from the total weight. Waist and hip
circumference were measured with the participant in a
standing position using a D-loop tape. Waist circum-
ference was measured at the mid-point between the lower
costal margin and the level of the anterior superior iliac
crest to the nearest millimetre and hip circumference was
measured at the widest level of the hips. Waist and hip
measurements were completed twice. If the difference
between two consecutive measurements was more than
3 cm, a third measurement was taken. The mean of the
two closest measurements constitutes the values of waist
and hip circumference. Body fat percentage was assessed by
bio-electrical impedance using the TANITA analyser. Mea-
surements were registered with the participant standing
barefoot on the weighing platform. Participants with pace-
makers or other internal medical devices were measured
only using SECA scales.
Body fat distribution
Abdominal fat distribution and hepatic fat content were
assessed by ultrasonography (Logiq9 ultrasound machine,
GE Healthcare, Waukesha, WI, USA) at two study centres
(Steno Diabetes Center and Aarhus) [18,19]. With the par-
ticipant lying down, the transducer was placed on the
abdomen where the xiphoid line crosses the waist circum-
ference (described above). Measurements were performed
at the end of a quiet expiration using minimal pressure on
the transducer. Subcutaneous fat was recorded as the ver-
tical distance from the skin to the linea alba with a 9 L
(2.5-8.0 MHz) transducer in the transverse position.
Visceral fat was recorded at the same location, with a 4 C
(1.5-4.5 MHz) transducer placed longitudinally, as the ver-
tical distance from the peritoneum to the front edge of the
vertebra. In order to quantify hepatic fat content an image
of the liver was captured intercostally with the participant
in the supine position, with the right arm held above the
head. A curved array 4 C transducer (3 MHz) was used.
All ultrasound machine settings were standardised to allow
subsequent analysis of image characteristics to quantify
hepatic fat content.
Objectively measured physical activity
Physical activity was measured using a combined accele-
rometer and heart rate monitor (ActiHeartW, CamNTech
Ltd., Cambridge, United Kingdom) [20]. The monitor was
placed horizontally on the participants’ chest on two
standard electrocardiogram electrodes (Maxensor, Alton,
United Kingdom), one at the lower part of the sternum
and the other one on the same horizontal level, on the left
side, as laterally as possible. On the day of the health
examination, a sub-maximal step test was performed to
allow individual calibration of the heart rate to physical
activity intensity [21]. The eight-minute step test was
Table 2 Measures used at the screening phase (2001–06)
and at the health assessment (2009–11) in the ADDITION-
PRO study
Screening
phase: low
risk1
participants
Screening
phase:
high
risk2
participants
ADDITION-
PRO health
assessment
Danish risk score
questionnaire
X X X
Socio-demographic variables
Age X X X
Sex X X X
Biochemistry
Random capillary blood
glucose
X
Fasting capillary blood
glucose3
X
Venous glycated
haemoglobin (HbA1c)
X X
75 g oral glucose tolerance
test3,4
X X
Insulin X
Total cholesterol X X
LDL-cholesterol X X
HDL-cholesterol X X
Triglycerides X X
Plasma and urine
creatinine3
X X
Urine albumin3 X X
DNA3 X X
Alanine transaminase X
Alkaline phosphatase X
Biobank: plasma, serum,
spot urine3
X X
Whole saliva5 X
Clinical measures
Electrocardiogram X
Heart rate X
Brachial blood pressure X X
Central blood pressure X
Aortic pulse wave velocity X
Advanced glycation end-
products
X
Anthropometric variables
Height X X
Weight X X
Waist circumference X X
Hip circumference X X
Body fat percentage X
Abdominal fat distribution
by ultrasound6
X
Table 2 Measures used at the screening phase (2001–06)
and at the health assessment (2009–11) in the ADDITION-
PRO study (Continued)
Hepatic fat content by
ultrasound6
X
Physical activity
Combined accelerometer
and heart rate monitor
(ActiHeart)
X
Recent physical activity
questionnaire (RPAQ)
X
Sleep questionnaire7 X
Questionnaire measures
Ethnicity / nationality X
Education X
Occupation X X
Personal medical history X X
Family history of diabetes X X X
Family history of CVD X X
Current medication X
Recent hospital admissions X
Gestational diabetes
(women only)
X X X
Lifestyle behaviours
(smoking, alcohol
consumption, physical
activity)
X X
Current weight, birth
weight, weight loss/gain,
perceived body image
X
EuroQol 5-D (health utility) X
SF-36 (functional status) X
Registry information X
Cardiovascular disease X X X
Type 2 diabetes X X X
Medication use X X X
Health service use X X X
Mortality X
1 Low diabetes risk <5 points on the diabetes risk score.
2 High diabetes risk ≥5 points on the diabetes risk score.
3 At screening, only for individuals with elevated RBG/FBG levels who
progressed through to the later stages of the screening programme.
4 At ADDITION-PRO, only for individuals without incident diabetes since screening.
5 Only collected at the Steno Diabetes Center.
6 Only collected at the Steno Diabetes Center and in Aarhus.
7 Collected at the Steno Diabetes Center, Esbjerg and Aarhus from July 2010.
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cycles of stepping up and down a 20.5 cm step bench
(Rucanor Europe B.V., Nieuwerkerk, The Netherlands).
The stepping frequency ranged from 15 to 33 step cycles
per minute over the duration of the test (8-minutes), fol-
lowed by a two-minute recovery period (sitting). After the
participant had completed the step test, the monitor was
Table 3 Conversion of biochemical measures in the
ADDITION-PRO study
Biochemical measure Equation
Glucose x = (y + 0.2637) / 0.983
Alkaline phosphatase x = (y-8.7108) / 1.0465
Alanine transaminase x = (y + 0.7823) / 0.9761
Plasma creatinine x = (y-2.7403) / 1.0147
HDL cholesterol x = (y + 0.2141) / 1.1254
Triglycerides x = (y + 0.0196) / 1.1017
Total cholesterol x = (1.0303*y-0.2362)
Urine albumin x = (0.8861*y-0.6412)
Urine creatinine x = (y-111.72) / 1.0087
x = value measured by Hitachi 912 machine.
y = value measured by Vitros 5600 machine.
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movement and heart rate every 60 seconds. Participants
were asked to wear the monitor for seven days and nights
and to maintain their usual physical activity pattern during
the period. Alongside wearing the monitor, participants
were asked to fill in a log to register any non-wear time
and comments during the measuring period. Heart rate
and accelerometry measures from the Actiheart monitor
were downloaded using the manufacturer’s software (www.
camntech.com). These measures were then cleaned and
processed to reduce noise, outliers, and incomplete heart
rate measures [22]. Physical activity measures were derived
by combining minute-to-minute heart rate and accelero-
metry measures using a branched equation model [23].
Biochemical measures
Spot urine for analysis of albumin and creatinine was
collected in plastic containers. Venous blood samples were
drawn after an overnight fast (≥8 hours). Participants
without known diabetes underwent a standard 75 g OGTT
with blood samples drawn at 30 and 120 minutes. Plasma
for analysis of glucose was prepared immediately upon
collection in fluoride-heparin coated tubes. Samples were
placed on ice before centrifugation at 3000 rpm for 10 min-
utes at 4°C. Plasma for analysis of creatinine, total choles-
terol, HDL-cholesterol, and triglycerides was prepared
upon collection in lithium-heparin coated tubes by incubat-
ing for 0.5-1.5 hours at room temperature with subsequent
centrifugation at 3000 rpm for 10 minutes without cooling.
Serum for analysis of insulin was prepared by incubating
whole blood for 0.5-1.5 hours at room temperature with
subsequent centrifugation for 10 minutes at 3000 rpm
without cooling. Whole blood for analysis of HbA1c and
DNA was collected in EDTA coated tubes. Additionally, ali-
quots of plasma (0, 30, 120 min), serum (0, 30, 120) and
spot urine were collected for the ADDITION-PRO biobank.
Plasma for the biobank was collected in chilled EDTA
coated tubes and centrifuged within 30 minutes at
3000 rpm for 10 minutes at 4°C. Biobank samples were
subsequently stored at −80°C.
All biochemical measures were analysed at the Clinical
Chemistry Department at the Steno Diabetes Center in
Gentofte, Denmark. Serum insulin was measured by im-
munoassay (AutoDELFIA, Perkin Elmer, Massachusetts,
United States). Glycated haemoglobin A1c (HbA1c) was
measured by HPLC (TOSOH G7, Tokyo, Japan). Between
2009 and 2010, plasma glucose, alanine transaminase,
alkaline phosphatase, total cholesterol, HDL-cholesterol,
triglycerides, plasma creatinine, urine creatinine and urine
albumin were measured using the Hitachi 912 system
(Roche Diagnostics, Mannheim, Germany). During 2010,
the study laboratory gradually implemented the Vitros
5600 Integrated System (Ortho Clinical Diagnostics,
Illkirch Cedex, France). There was modest agreementbetween the Hitachi 912 and Vitros 5600 instruments.
Thus, all ‘Vitros’ values were converted to correspond to
‘Hitachi’ values, using regression equations from validation
analyses performed by the study laboratory (Table 3).
Albumin creatinine ratio was calculated using the for-
mula: U-albumin mg/l × 8.84)/(U-creatinine(μmol/l)/1000).
VLDL cholesterol (VLDL-C) was calculated using the for-
mula: VLDL-C = triglycerides (mmol/l)/2.2). VLDL-C was
calculated only for triglyceride values ≤ 5.05 mmol/l. LDL
cholesterol was calculated using Friedewald’s equation
(LDL-C = TC – VLDL-C – HDL-C mmol/l) [24]. LDL-
cholesterol was calculated only for triglyceride values
≤ 4.55 mmol/l.
Collection of whole saliva was performed at one of the
study centres (Steno Diabetes Centre). Participants were
asked not to brush teeth on the day of the health assess-
ment. Upon arrival, participants were instructed to chew
on paraffin wax for approximately one minute and then
to empty their mouth of saliva. The participants were
then instructed to chew on the paraffin wax for a further
three minutes whilst spitting into a collection container
whenever needed. The collected saliva was divided into
two cryotubes. One tube was stored immediately at
−80°C. RNAlater (Ambion, Austin, TX) was added to
the second tube in a 1:3 ratio (saliva:RNAlater) and then
refrigerated for approximately 24 hours before being
transferred to −80°C storage.
Questionnaires
A general health questionnaire was mailed to each par-
ticipant in advance of their measurement visit. The
questionnaire included sections on personal medical
history, family history of diabetes / CVD, and lifestyle
behaviours (smoking status, weekly alcohol consump-
tion, and physical activity). There were questions on
current weight, birth weight, weight loss / gain and per-
ceived body image, as well as commuting, occupational
and leisure time physical activity habits throughout the
Table 4 Power calculations for main outcomes in the
ADDITION-PRO study
Expected
CVD
events (n)
Expected incidence
rate (per 1000
person years)
Power
Difference in CVD
incidence between:
NGT and stable
IFG/IGT
53 7.4 0.97
NGT and incident DM 100 13.8 0.99
Stable IFG/IGT and
incident diabetes
132 18.3 0.59
Detectable
differences
Expected mean (SD)
in reference group
(NGT)
Power
Aortic stiffness (pulse
wave velocity)
0.4 m/s 7.5 m/s (2.5) 0.94
Renal function (eGFR) 5 ml/min/
1.73 m2
100 ml/min/1.73 m2
(20)
0.98
AGE – (skin
autofluorescence)
0.2 AU 2.0 AU (0.5) 0.94
AGE = advanced glycation end-products; CVD = cardiovascular disease;
eGFR = estimated glomerular filtration rate; IFG = impaired fasting glucose;
IGT = impaired glucose tolerance; NGT = normal glucose tolerance.
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(EQ-5D) health utility measure [25] and the SF-36 func-
tional status measure [26]. Socio-demographic questions
included age, occupation, nationality, and ethnicity. Data
on current medication and recent hospital admittance
were also collected. Medication was coded by a super-
vised nurse according to the Danish formulary (http://
medicin.dk). Female participants were asked for details
on the number of pregnancies and live births they had
experienced, and for the number and birth weight of
their children. They reported if they had developed ges-
tational diabetes.
Physical activity during the last four weeks prior to fill-
ing out the questionnaire was assessed using a modified
Danish version of the validated “recent physical activity
questionnaire” (RPAQ) [27]. From July 2010 onwards a
detailed sleep questionnaire was completed alongside
combined heart rate and accelerometry measurement.
All questionnaires were checked for completeness before
the participant finished their measurement visit. The
clinical research forms, general health questionnaire and
RPAQ were scanned using a Teleform reader and veri-
fied manually. Double data entry of the sleep question-
naire was undertaken by experienced research assistants.
All data were checked for outliers and nonsense
values and cleaned before being uploaded to the
study database.
Registry data
Data will be drawn from the unique register system in
Denmark. The Danish National Civil Registry assigns a
personal Civil Registration Number to all citizens in
Denmark. All Danish citizens have National Health
Insurance and are entitled to free access to medical care
from general practice and hospitals. Data from different
sources can be combined using the civil registration
number. We will access the following registries to collect
information on incident CVD, incident diabetes, mortality,
medication and health service usage: the National Patient
Registry (covering admissions and outpatient contacts to
the hospitals), the National Health Service Registry (con-
tacts in general practice), the Medical Prescription Regis-
try, the Diabetes Registry, and the Death Cause Registry
(based on death certificates, 100% coverage).
Sample size
Based on prior experience in the use of Statistics Denmark
linkage for event follow up, we expect to achieve a 90%
completeness of follow up for CVD events and a 100%
completeness of follow up for mortality. Table 4 shows the
power calculations performed prior to the start of the cli-
nical examinations. The expected number of events in the
ADDITION-PRO population was based on incidence rates
and hazard ratios reported by the Hoorn study [28]. Basedon expected mortality and attrition due to loss to follow
up, we aimed to examine 1,800 participants who had IFG/
IGT at screening, over half of whom were expected to
progress to diabetes during follow-up. Adding a random
subset of 900 participants who had normoglycaemia at
screening yielded ample power to detect differences in
CVD risk between the normoglycaemic group and the
stable IFG/IGT and incident diabetes group, respectively.
We examined 77% of the target population. One of the
original ADDITION-DK study centres did not participate
in the ADDITION-PRO health assessment and there was a
lower than expected participation rate (50% rather than
the expected 75%) amongst the group of participants with
IFG/IGT. While the difference in CVD incidence between
the stable IFG/IGT group and the incident diabetes group
is expected to be smaller, comparison of the continuous
measures of atherosclerosis, renal function and AGE accu-
mulation will be sufficiently powered to highlight even
small differences between all study groups.
Discussion
The ADDITION-PRO study is designed to increase under-
standing of CVD risk and its underlying mechanisms
among individuals at high risk of diabetes recruited from a
stepwise screening programme in Danish primary care. Key
features of this study include (i) a carefully characterised
cohort at different levels of diabetes risk; (ii) detailed meas-
urement of anthropometric, body composition, biochemical
and cardiovascular risk factors; (iii) objective measurement
of physical activity behaviour; (iv) examination of the initial
stages of micro- and macrovascular complications; and
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mortality and CVD. Results will inform policy recommen-
dations concerning CVD risk reduction and treatment
among individuals at high risk for diabetes. The detailed
phenotyping of this cohort will also allow a number of
research questions concerning early changes in cardiometa-
bolic physiology to be addressed.
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